Compare · LIFE vs MEIP
LIFE vs MEIP
Side-by-side comparison of Ethos Technologies Inc. (LIFE) and MEI Pharma Inc. (MEIP): market cap, price performance, sector, and recent activity on the wire.
Summary
- LIFE operates in Finance, while MEIP operates in Health Care - the two are in different parts of the market.
- LIFE is the larger of the two at $2.46B, about 9.7x MEIP ($253.7M).
- LIFE has hit the wire 29 times in the past 4 weeks while MEIP has been quiet.
- LIFE has more recent analyst coverage (17 ratings vs 5 for MEIP).
- Company
- Ethos Technologies Inc.
- MEI Pharma Inc.
- Price
- -
- -
- Market cap
- $2.46B
- $253.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Specialty Insurers
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2026
- 2003
- News (4w)
- 29
- 0
- Recent ratings
- 17
- 5
Ethos Technologies Inc.
aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product, ATYR1923, is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of various aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
MEI Pharma Inc.
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California.
Latest LIFE
- Large owner Sc Us (Ttgp), Ltd. converted options into 1,778,626 shares and disposed of 1,778,626 shares (SEC Form 4)
- Director Botha Roelof acquired 55,167 shares (SEC Form 4)
- CEO and Secretary Colis Peter George converted options into 55,848 shares and sold $2,795,706 worth of shares (84,448 units at $33.11) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,537,360 units (SEC Form 4)
- President Wang Lingke converted options into 83,197 shares and sold $3,939,733 worth of shares (118,333 units at $33.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,537,543 units (SEC Form 4)
- Chief Accounting Officer Kucharski Brandt Walter sold $283,664 worth of shares (8,735 units at $32.47) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 91,648 units (SEC Form 4)
- Large owner Sc Us (Ttgp), Ltd. converted options into 142,616 shares and sold $4,713,232 worth of shares (142,616 units at $33.05) (SEC Form 4)
- Large owner Sc Us (Ttgp), Ltd. sold $4,713,232 worth of shares (142,616 units at $33.05) and converted options into 142,616 shares (SEC Form 4)
- SEC Form 144 filed by Ethos Technologies Inc.
- Director Botha Roelof acquired 51,735 shares (SEC Form 4)
- Large owner Sc Us (Ttgp), Ltd. converted options into 1,778,626 shares and disposed of 1,778,626 shares (SEC Form 4)
Latest MEIP
- MEI Pharma Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities
- New insider Schornstein Alexander claimed ownership of 4,365,472 shares (SEC Form 3)
- MEI Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker 'LITS'
- SEC Form EFFECT filed by MEI Pharma Inc.
- SEC Form 424B3 filed by MEI Pharma Inc.
- MEI Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Amendment: SEC Form S-3/A filed by MEI Pharma Inc.
- SEC Form 4 filed by Director Riezman Joshua
- SEC Form 3 filed by new insider Riezman Joshua